Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the first-to-market launch of over-the-counter (OTC) Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D® 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).
"The launch of Dr. Reddy's Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, is an important addition to our upper respiratory portfolio of OTC products," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories. "This first-to-market launch is a testament to our deep capabilities and our continued efforts to bring high quality, affordable store-brand alternatives for our customers and patients."
Dr. Reddy's OTC Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP is an over-the-counter oral antihistamine and nasal decongestant for the temporary relief of nasal and sinus congestion due to colds or allergies. It temporarily relieves sneezing; runny nose; itchy, watery eyes; and itchy nose or throat due to allergies.
Allegra-D® 24 HR had U.S. retail sales of approximately $45 million as of May 2022 according to IRI*.
Dr. Reddy's OTC Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP will be available in 5-count, 10-count, and 15-count pack sizes.
Allegra-D® is a registered trademark of Aventisub LLC.
Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4373.00 as compared to the previous close of Rs. 4457.45. The total number of shares traded during the day was 6659 in over 1336 trades.
The stock hit an intraday high of Rs. 4481.85 and intraday low of 4360.45. The net turnover during the day was Rs. 29464255.00.